Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATG Dose Study for aGVHD Prophylaxis in Haploidentical HSCT
NCT02643589Unknown
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Jun 2013
- Primary completion
- Jun 2016
- Countries
- 1
01
Overview
Randomised, open-label trial of antithymocyte globulin in Acute Graft-Versus-Host Disease (aGVHD) (2 arms), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Incidence of acute Graft-versus-host Disease at 1 year. Status: unknown.
02
Drugs
antithymocyte globulin
03
Conditions
Acute Graft-Versus-Host Disease (aGVHD)
Beyond the preview
Go deeper on NCT02643589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02643589.